Page 2 - Lishan Su News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Inceptor Bio Launches FastBack Bio, Its First Portfolio Company Developing A Novel CAR-T Platform That Targets Difficult-To-Treat Cancers

Inceptor Bio Launches FastBack Bio, Its First Portfolio Company Developing A Novel CAR-T Platform That Targets Difficult-To-Treat Cancers
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesChapel hillAbe maingiLishan suMike nicholsonUniversity of north carolina at chapel hillLineberger cancer centerUniversity of north carolinaDepartment of microbiology immunologyChief science officerInceptor bioBack bioNorth carolinaCancer centerMaryland instituteFastback bio

Inceptor Bio : Launches FastBack Bio, Its First Portfolio Company Developing A Novel CAR-T Platform That Targets Difficult-To-Treat Cancers

Inceptor Bio : Launches FastBack Bio, Its First Portfolio Company Developing A Novel CAR-T Platform That Targets Difficult-To-Treat Cancers
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesChapel hillAbe maingiLishan suMike nicholsonUniversity of north carolina at chapel hillResearch triangle parkLineberger cancer centerUniversity of north carolinaDepartment of microbiology immunologyInceptor bioNorth carolina basedFastback bioBack bioChief science officerNorth carolina

Diabetes drug metformin may be a new weapon against HIV

A team led by scientists at the UNC School of Medicine discovered an important vulnerability of the AIDS-causing retrovirus HIV and has shown in preclinical experiments that a widely used diabetes drug, metformin, seems able to exploit this vulnerability. The scientists, whose study is published in Nature Immunology, found that HIV, when it infects immune cells called CD4 T cells, helps fuel its own replication by boosting a key process in the cells’ production of chemical energy. They also found that the diabetes drug metformin inhibits the same process and thereby suppresses HIV replication in these cells, in both cell-culture and mouse experiments.

Chapel hillRafick pierre sekalyHaitao guoWilliamr kenan jrLishan suQi wangSchool of medicineUniversity of maryland school medicineKhader ghneim at case western universityWorld health organizationDepartment of geneticsNature immunologyJenny tingDistinguished professorMaryland schoolKhader ghneim

Diabetes drug appears to exploit vulnerability of AIDS-causing retrovirus HIV

Diabetes drug appears to exploit vulnerability of AIDS-causing retrovirus HIV
news-medical.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from news-medical.net Daily Mail and Mail on Sunday newspapers.

Chapel hillRafick pierre sekalyHaitao guoWilliamr kenan jrLishan suQi wangEmily hendersonSchool of medicineUniversity of maryland school medicineStudy coKhader ghneim at case western universityWorld health organizationDepartment of geneticsNature immunologyStudy co first authorAssistant professor

citybizlist : New York : Drug Farm Closes $56M Financing

2/9/21 Drug Farm, a China- and US-based biotechnology company utilizing genetics and AI technologies to discover and develop innovative, immune-modulating therapies, has completed financing totaling $56 million USD. This funding will enable the Company to initiate human clinical trials with its lead drug DF-006, a first-in-class, orally bioavailable drug for hepatitis B virus (HBV) infection and other liver diseases. The financing will also be used to further advance Drug Farm’s additional pipeline candidates for therapies in cancer and autoimmune diseases. Drug Farm investors include BioVeda China Fund (BVCF), WuXi AppTec’s corporate venture fund, South China Venture Capital (SCVC), Detong Capital, and Zhejiang United Investment Group (ZUIG).

Henri lichensteinLishan suCancer of the institute human virologyUniversity of maryland school medicineZhejiang united investment groupDivision of virologyBioveda china fundDrug farmWuxi apptecSouth china venture capitalDetong capitalBoard memberDrug farm scientific advisory boardHuman virologyMaryland schoolலிஷன் சு